A Phase 2 Extension Study of Study GCS-100-CS-4002

Trial Profile

A Phase 2 Extension Study of Study GCS-100-CS-4002

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 01 Sep 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top